Skip to main content
. 2023 Oct 6;14:1226936. doi: 10.3389/fphar.2023.1226936

TABLE 4.

Estimation of PK/PD parameters derived from the inhibitory sigmoidal Emax model.

PK/PD parameter E0 (log10 CFU/mL) EC50 Emax (log10 CFU/mL) Hill coefficient R2 3 Log10 CFU/mL reduction
Enrofloxacin alone
AUC24h/MIC (h) −3.64 24.00 2.90 5.51 0.917 23.29
Cmax/MIC −4.60 3.92 3.06 2.09 0.951 3.18
%T > MIC −5.90 72.47 2.67 4.28 0.936 62.71
Cefquinome alone
AUC24h/MIC (h) −1.81 6.06 2.25 29.19 0.957 6.28
Cmax/MIC −1.81 4.01 2.25 10.25 0.948 4.44
%T > MIC −2.32 46.50 2.32 13.28 0.995 48.66
Cefquinome in combination with enrofloxacin
AUC24h/MIC (h) −2.98 5.06 2.29 3.82 0.941 4.78
Cmax/MIC −2.84 2.42 2.25 14.78 0.936 2.54
%T > MIC −3.35 17.43 2.32 3.41 0.959 18.04

Emax is the change in the control group (log10 CFU/mL) from 0 h to 24 h; E0 is the maximum value of the antibacterial effect; EC50 is the corresponding PK/PD, index that produces a 50% reduction of the maximum antibacterial effect; N is the Hill coefficient. The “3 Log10 CFU/mL reduction” is the PK/PD, index value calculated after a decrease of 3 Log10 CFU/mL in Emax.